Skip to main content

Table 2 Cx26/Cx32 expression in clinical samples and their correlation with patients’ clinical outcomes

From: Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application

Cancer Type Clinical manifest Ref.
Cx26 in primary tumor tissues
 Breast Cytoplasmic Cx26; associated with lymphatic vessel invasion and poor relapse-free survival [63]
Colorectal Cytoplasmic Cx26; associated with venous invasion, lung metastasis, and poor disease-free survival [64]
 FTC Cytoplasmic Cx26; associated with lymph node metastasis [65]
 PTC Cytoplasmic Cx26; associated with high incidence of intra-glandular dissemination [65]
 ESCC Cytoplasmic Cx26; associated with lymph node metastasis and poor 5-year survival [66]
Melanoma Cx26 mRNA; associated with poor survival [24]
 Breast Cx26 mRNA; associated with recurrence [24]
Cx26 in metastatic lesions
 Breast Cell surface Cx26; increased expression in lymph node metastases; cell surface Cx26 was only found in metastatic lesions [18]
 Colorectal Cytoplasmic Cx26; increased expression in lung metastatic lesions [64]
Cx32 in primary tumor tissues
 HCC Cx32 mRNA; reversely correlated with histological grade and lymph node metastasis [78]
Cx32 mRNA; associated with low vascular invasion and high overall survival rate [79]
Cx32 in metastatic lesions
 Breast Cytoplasmic Cx32; increased expression in metastatic lymph nodes [70]
  1. FTC Follicular thyroid cancer, PTC Papillary thyroid cancer, ESCC Esophageal squamous cell carcinoma, NSCLC Non-small cell lung cancer, HCC Hepatocellular carcinoma